Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.12.6557 on October 29 2007

Journal of Clinical Oncology, Vol 25, No 33 (November 20), 2007: pp. 5210-5217
© 2007 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thomas, E. S.
Right arrow Articles by Roché, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomas, E. S.
Right arrow Articles by Roché, H. H.
Related Articles
Right arrowRelated Correspondence
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

Eva S. Thomas, Henry L. Gomez, Rubi K. Li, Hyun-Cheol Chung, Luis E. Fein, Valorie F. Chan, Jacek Jassem, Xavier B. Pivot, Judith V. Klimovsky, Fernando Hurtado de Mendoza, Binghe Xu, Mario Campone, Guillermo L. Lerzo, Ronald A. Peck, Pralay Mukhopadhyay, Linda T. Vahdat, Henri H. Roché

From the M.D. Anderson Cancer Center, Houston, TX; Instituto Nacional de Enfermedades Neoplasicas; Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; St Luke's Medical Center; Veterans Memorial Medical Center, Quezon City, Philippines; Yonsei Cancer Center, Seoul, Republic of Korea; Centro de Oncologia Rosario, Sante Fe; Hospital de Oncologia ‘Maria Curie,’ Buenos Aires, Argentina; Medical University of Gdansk, Gdansk, Poland; C.H.U. Jean Minjoz, Besançon; Centre Rene Gauducheau, Nantes; Institut Claudius Regaud, Toulouse, France; Bristol-Myers Squibb, Research and Development, Wallingford, CT; Cancer Hospital –Chinese Academy of Medical Sciences, Beijing, China; and Weill Medical College of Cornell University, New York, NY

Address reprint requests to Eva S. Thomas, MD, 280 West MacArthur Blvd, Oakland, CA 94611; e-mail: eva.s.thomas{at}kp.org

Purpose Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Ixabepilone has single-agent activity in these patients and has demonstrated synergy with capecitabine in this setting. This study was designed to compare ixabepilone plus capecitabine versus capecitabine alone in anthracycline-pretreated or -resistant and taxane-resistant locally advanced or metastatic breast cancer.

Patients and Methods Seven hundred fifty-two patients were randomly assigned to ixabepilone 40 mg/m2 intravenously on day 1 of a 21-day cycle plus capecitabine 2,000 mg/m2 orally on days 1 through 14 of a 21-day cycle, or capecitabine alone 2,500 mg/m2 on the same schedule, in this international phase III study. The primary end point was progression-free survival evaluated by blinded independent review.

Results Ixabepilone plus capecitabine prolonged progression-free survival relative to capecitabine (median, 5.8 v 4.2 months), with a 25% reduction in the estimated risk of disease progression (hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P = .0003). Objective response rate was also increased (35% v 14%; P < .0001). Grade 3/4 treatment-related sensory neuropathy (21% v 0%), fatigue (9% v 3%), and neutropenia (68% v 11%) were more frequent with combination therapy, as was the rate of death as a result of toxicity (3% v 1%, with patients with liver dysfunction [≥ grade 2 liver function tests] at greater risk). Capecitabine-related toxicities were similar for both treatment groups.

Conclusion Ixabepilone plus capecitabine demonstrates superior efficacy to capecitabine alone in patients with metastatic breast cancer pretreated or resistant to anthracyclines and resistant to taxanes.

published online ahead of print at www.jco.org on October 29, 2007.

Supported by Bristol-Myers Squibb. Interim efficacy and safety analyses were supervised by an independent data-monitoring committee. The authors vouch for the completeness and accuracy of results presented.

Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 3, 2007, Chicago, IL.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Correspondence

  • Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
    Eva S. Thomas
    JCO 2008 26: 2223 [Full Text]


This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
J. Schwartz
Current combination chemotherapy regimens for metastatic breast cancer
Am. J. Health Syst. Pharm., December 1, 2009; 66(23_Supplement_6): S3 - S8.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
E. D. Saad, A. Katz, P. M. Hoff, and M. Buyse
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
Ann. Onc., November 9, 2009; (2009) mdp523v1.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, et al.
Third consensus on medical treatment of metastatic breast cancer
Ann. Onc., November 1, 2009; 20(11): 1771 - 1785.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
P. Schmid, P. Kiewe, K. Possinger, A. Korfel, S. Lindemann, M. Giurescu, S. Reif, H. Wiesinger, E. Thiel, and D. Kuhnhardt
Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors
Ann. Onc., October 30, 2009; (2009) mdp491v1.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. Gray, S. Bhattacharya, C. Bowden, K. Miller, and R. L. Comis
Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer
J. Clin. Oncol., October 20, 2009; 27(30): 4966 - 4972.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. A. Sparano, A. N. Makhson, V. F. Semiglazov, S. A. Tjulandin, O. I. Balashova, I. N. Bondarenko, N. V. Bogdanova, G. M. Manikhas, G. P. Oliynychenko, V. A. Chatikhine, et al.
Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
J. Clin. Oncol., September 20, 2009; 27(27): 4522 - 4529.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
F. Cardoso, P. L. Bedard, E. P. Winer, O. Pagani, E. Senkus-Konefka, L. J. Fallowfield, S. Kyriakides, A. Costa, T. Cufer, K. S. Albain, et al.
International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
J Natl Cancer Inst, September 2, 2009; 101(17): 1174 - 1181.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. A. Perez
Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
Mol. Cancer Ther., August 1, 2009; 8(8): 2086 - 2095.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
W. W. Tan, D. W. Hillman, M. Salim, D. W. Northfelt, D. M. Anderson, P. J. Stella, R. Niedringhaus, A. M. Bernath, S. S. Gamini, F. Palmieri, et al.
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial
Ann. Onc., July 22, 2009; (2009) mdp328v1.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Sabbatini and D. R. Spriggs
Epothilones: Better or More of the Same?
J. Clin. Oncol., July 1, 2009; 27(19): 3079 - 3081.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
L. B. Michaud
The Epothilones: How Pharmacology Relates to Clinical Utility
Ann. Pharmacother., July 1, 2009; 43(7): 1294 - 1309.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
V. Guarneri and P. Conte
Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy
Oncologist, July 1, 2009; 14(7): 645 - 656.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Jimeno
Eribulin: Rediscovering Tubulin as an Anticancer Target
Clin. Cancer Res., June 15, 2009; 15(12): 3903 - 3905.
[Abstract] [Full Text] [PDF]


Home page
J Oncol Pharm PractHome page
L. Boehnke Michaud
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer
Journal of Oncology Pharmacy Practice, June 1, 2009; 15(2): 95 - 106.
[Abstract] [PDF]


Home page
Mayo Clin Proc.Home page
A. Moreno-Aspitia and E. A. Perez
Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane
Mayo Clin. Proc., June 1, 2009; 84(6): 533 - 545.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. D. Reed, Y. Li, K. J. Anstrom, and K. A. Schulman
Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
J. Clin. Oncol., May 1, 2009; 27(13): 2185 - 2191.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. E. Hillner and T. J. Smith
Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing
J. Clin. Oncol., May 1, 2009; 27(13): 2111 - 2113.
[Full Text] [PDF]


Home page
The OncologistHome page
D. A. Yardley
Proactive Management of Adverse Events Maintains the Clinical Benefit of Ixabepilone
Oncologist, May 1, 2009; 14(5): 448 - 455.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
E. D. Saad and A. Katz
Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined
Ann. Onc., March 1, 2009; 20(3): 460 - 464.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. Winer, J. Gralow, L. Diller, B. Karlan, P. Loehrer, L. Pierce, G. Demetri, P. Ganz, B. Kramer, M. Kris, et al.
Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening--A Report From the American Society of Clinical Oncology
J. Clin. Oncol., February 10, 2009; 27(5): 812 - 826.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Baselga, M. Zambetti, A. Llombart-Cussac, G. Manikhas, E. Kubista, G. G. Steger, A. Makhson, S. Tjulandin, H. Ludwig, M. Verrill, et al.
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
J. Clin. Oncol., February 1, 2009; 27(4): 526 - 534.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. Dumontet, M. A. Jordan, and F. F.Y. Lee
Ixabepilone: targeting {beta}III-tubulin expression in taxane-resistant malignancies
Mol. Cancer Ther., January 1, 2009; 8(1): 17 - 25.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Plummer, P. Woll, D. Fyfe, A. V. Boddy, M. Griffin, P. Hewitt, J. Carmichael, F. Namouni, M. Cohen, and M. Verrill
A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies
Clin. Cancer Res., December 15, 2008; 14(24): 8288 - 8294.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. Goel, G. L. Goldberg, D. Y.-S. Kuo, F. Muggia, J. Arezzo, and S. Mani
Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone
Ann. Onc., December 1, 2008; 19(12): 2048 - 2052.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
E. Rivera, J. Lee, and A. Davies
Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors
Oncologist, December 1, 2008; 13(12): 1207 - 1223.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. G. Morris and M. N. Fornier
Microtubule Active Agents: Beyond the Taxane Frontier
Clin. Cancer Res., November 15, 2008; 14(22): 7167 - 7172.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
S. Goodin
Ixabepilone: A novel microtubule-stabilizing agent for the treatment of metastatic breast cancer
Am. J. Health Syst. Pharm., November 1, 2008; 65(21): 2017 - 2026.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. R. Tan and D. L. Toppmeyer
Ixabepilone in Metastatic Breast Cancer: Complement or Alternative to Taxanes?
Clin. Cancer Res., November 1, 2008; 14(21): 6725 - 6729.
[Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
P. M. Wilson, W. Fazzone, M. J. LaBonte, J. Deng, N. Neamati, and R. D. Ladner
Novel opportunities for thymidylate metabolism as a therapeutic target
Mol. Cancer Ther., September 1, 2008; 7(9): 3029 - 3037.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
S. Bhushan and C. M Walko
Ixabepilone: A New Antimitotic for the Treatment of Metastatic Breast Cancer
Ann. Pharmacother., September 1, 2008; 42(9): 1252 - 1261.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. E. Dodd, E. L. Korn, B. Freidlin, C. C. Jaffe, L. V. Rubinstein, J. Dancey, and M. M. Mooney
Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?
J. Clin. Oncol., August 1, 2008; 26(22): 3791 - 3796.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
S. Goodin
Novel cytotoxic agents: Epothilones
Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S10 - S15.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
S. Y. Barbour
Caring for the treatment-experienced breast cancer patient: The pharmacist's role
Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S16 - S22.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. S. Thomas
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
J. Clin. Oncol., May 1, 2008; 26(13): 2223 - 2223.
[Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
J. R. Murillo Jr, J. E. Cox, and M. S. Oholendt
An Overview of Chemotherapy-Induced Peripheral Neuropathy
Journal of Pharmacy Practice, April 1, 2008; 21(2): 138 - 145.
[Abstract] [PDF]


Home page
Clin. Cancer Res.Home page
J. J. Lee and S. M. Swain
The Epothilones: Translating from the Laboratory to the Clinic
Clin. Cancer Res., March 15, 2008; 14(6): 1618 - 1624.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
L. Vahdat
Ixabepilone: A Novel Antineoplastic Agent with Low Susceptibility to Multiple Tumor Resistance Mechanisms
Oncologist, March 1, 2008; 13(3): 214 - 221.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
E. J. Wasserman and A. R. Tan
Evolving Strategies for the Treatment of "Triple-Negative" Breast Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 120 - 126.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online